Delpharm, a CDMO, has expanded its pharmaceutical development services with the acquisition of the Leiden Development Center from Dr Reddy’s in the Netherlands. This center employs forty highly qualified personnel and is located in a 3,500 square meter unit equipped with state-of-the-art technologies to develop injectable formulation for small and large molecules and to manufacture small batches for clinical trials.
 
With the acquisition of the Leiden site, Delpharm has expanded its scale for injectables, from formulation, analytical development, phase 1 clinical batches manufacturing, through regulatory affairs, to production in one of the group’s four injectable plants. This include three in France and one in Canada.
 
Delpharm offers services for the development and production of injectable drugs in all major sterile dosage forms (aseptic filling and /or terminal sterilization): prefilled syringes, freeze drying, ampoules and vials. Delpharm also provides development and manufacturing of complex formulations such as liposome, suspension, microsphere, sustained release and emulsion.
 
“We are proud to acquire this center in Leiden which complements our development services’ offer, organized by technology platforms, for Injectable, Ophthalmic, Oral solid dose, Liquid and Semi solid drugs. We are also making significant investments in our injectable manufacturing facilities throughout the world to offer a one stop shop service to our clients, speeding up the access of new medicines for the patients,” said Jean-Bernard Dumas, Chief Scientific Officer.